Maspin Suppresses Survival of Lung Cancer Cells through Modulation of Akt Pathway
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose :Maspin is a tumor suppressor protein that has been reported to stimulate the cell death of cancer and inhibit the metastasis of cancer. The present study aimed to explore the survival pathway by which maspin modulates the resistance of human lung cancer cells to chemotherapeutic drugs, and the consequences of maspin gene therapy in an animal model. Materials and Methods :NCI-H157 and A549 cells were transfected with either a mock vector (pCMVTaq4C), maspin (pCMV-maspin), siControl or siMaspin. RT-PCR and Western blot analysis were performed to study the expressions of survival proteins in lung cancer. cDNA microarray analysis was carried out to compare the maspin-modulated gene expression between the xenograft tumors derived from the lung cancer cells that were stably transfected with pCMVTaq4C or pCMV-maspin. Maspin gene therapy was performed by intra-tumoral injections of pCMVTaq4C or pCMV-maspin into the pre-established subcutaneous tumors in nude mice. Results :Maspin significantly decreased the survival to doxorubicin and etoposide, whereas did not affect the survival to cisplatin in the NCI-H157 cells. Interestingly, transfection with a maspin plasmid resulted in a significant reduction of the phosphorylation of Akt in the NCI-H157 cells, whereas knockdown of maspin increased the phosphorylation of Akt in the A549 cells. Microarray analysis of the xenograft tumors revealed a specific gene expression profile, demonstrating that maspin is associated with the differential expressions of PTEN and IGF2R. Direct transfer of pCMV-maspin into the tumor significantly retarded the tumor growth in the animal experiments (p=0.0048). Conclusion :Lung cancer cells lacking maspin could be resistant to chemotherapeutic drugs such as doxorubicin or etoposide, at least in part by maintaining Akt phosphorylation.
Abstract
Purpose :Maspin is a tumor suppressor protein that has been reported to stimulate the cell death of cancer and inhibit the metastasis of cancer. The present study aimed to explore the survival pathway by which maspin modulates the resistance of human lung cancer cells to chemotherapeutic drugs, and the consequences of maspin gene therapy in an animal model. Materials and Methods :NCI-H157 and A549 cells were transfected with either a mock vector (pCMVTaq4C), maspin (pCMV-maspin), siControl or siMaspin. RT-PCR and Western blot analysis were performed to study the expressions of survival proteins in lung cancer. cDNA microarray analysis was carried out to compare the maspin-modulated gene expression between the xenograft tumors derived from the lung cancer cells that were stably transfected with pCMVTaq4C or pCMV-maspin. Maspin gene therapy was performed by intra-tumoral injections of pCMVTaq4C or pCMV-maspin into the pre-established subcutaneous tumors in nude mice. Results :Maspin significantly decreased the survival to doxorubicin and etoposide, whereas did not affect the survival to cisplatin in the NCI-H157 cells. Interestingly, transfection with a maspin plasmid resulted in a significant reduction of the phosphorylation of Akt in the NCI-H157 cells, whereas knockdown of maspin increased the phosphorylation of Akt in the A549 cells. Microarray analysis of the xenograft tumors revealed a specific gene expression profile, demonstrating that maspin is associated with the differential expressions of PTEN and IGF2R. Direct transfer of pCMV-maspin into the tumor significantly retarded the tumor growth in the animal experiments (p=0.0048). Conclusion :Lung cancer cells lacking maspin could be resistant to chemotherapeutic drugs such as doxorubicin or etoposide, at least in part by maintaining Akt phosphorylation.
참고문헌 (19)
- Schneider SS, "A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene", Proc Natl Acad Sci USA, 92, pp.3147~3151 (1995)
- Sheng S, "Production, purification, and characterization of recombinant maspin proteins", J Biol Chem, 269, pp.30988~30993 (1994)
- McGowen R, "The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin", Cancer Res, 60, pp.4771~4778 (2000)
- Pemberton PA, "The tumor suppressor maspin does not undergo the stressed to relaxed transition or inhibit trypsin-like serine proteases. Evidence that maspin is not a protease inhibitory serpin", J Biol Chem, 270, pp.15832~15837 (1995)
- Kim S, "Maspin expression is transactivated by p63 and is critical for the modulation of lung cancer progression", Cancer Res, 64, pp.6900~6905 (2004)
- Jang H, "Maspin polymorphism associated with susceptibility to apoptosis and in vivo tumorigenesis", Int J Mol Med, 22, pp.333~338 (2008)
- Liu J, "Bax mediates the apoptosis-sensitizing effect of maspin", Cancer Res, 64, pp.1703~1711 (2004)
- Zou Z, "Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells", Science, 263, pp.526~529 (1994)
- "Hendrix MJ. De-mystifying the mechanism(s) of maspin", Nat Med, 6, pp.374~376 (2000)
- Sheng S, "Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells", Proc Natl Acad Sci USA, 93, pp.11669~11674 (1996)
- Lawlor MA, "PKB", Akt: a key mediator of cell proliferation, survival and insulin responses, 2001, pp.114, 2903~2910
- Kang HC, "Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high- density oligonucleotide microarrays", Clin Cancer Res, 10, pp.272~284 (2004)
- Moorehead RA, "Influence of the proto-oncogene c-fos on cisplatin sensitivity", Biochem Pharmacol, 59, pp.337~345 (2000)
- Hettinga JV, "Heat-shock protein expression in cisplatin-sensitive and -resistant human tumor cells", Int J Cancer, 67, pp.800~807 (1996)
- Mizutani Y, "Enhancement of sensitivity ofurinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide", Cancer, 74, pp.2546~2554 (1994)
- Beale PJ, "BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma", Br J Cancer, 82, pp.436~440 (2000)
- Park C, "Lovastatin-induced E2F-1 modulation and its effect on gastric cancer cell death", Carcinogenesis, 22, pp.1727~1731 (2001)
- Jung HH, "STAT1 and Nmi are downstream targets of Ets-1 transcription factor in MCF-7 human breast cancer cell", FEBS Letters, 579, pp.3941~3946 (2005)
- Nicholson DW, "From bench to clinic with apoptosis-based therapeutic agents", Nature, 407, pp.810~816 (2000)